Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
HAT
MCID: HPR003
MIFTS: 47

Heparin-Induced Thrombocytopenia (HAT)

Categories: Blood diseases, Immune diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Heparin-Induced Thrombocytopenia

About this section

MalaCards integrated aliases for Heparin-Induced Thrombocytopenia:

Name: Heparin-Induced Thrombocytopenia 20 58 70
Hit 20 58
Heparin-Induced Thrombocytopenia Type 2 58
Heparin-Associated Thrombocytopenia 58
Hat 58

Characteristics:

Orphanet epidemiological data:

58
heparin-induced thrombocytopenia
Inheritance: Not applicable; Age of onset: All ages;

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Blood diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 33
Orphanet: 58  
Rare haematological diseases


External Ids:

ICD10 via Orphanet 33 D69.5
UMLS via Orphanet 71 C0272285
Orphanet 58 ORPHA3325
UMLS 70 C0272285
Sources

Summaries for Heparin-Induced Thrombocytopenia

About this section
GARD : 20 Heparin-induced thrombocytopenia (HIT) is an adverse reaction to the drug heparin resulting in an abnormally low amount of platelets ( thrombocytopenia ). HIT is usually an immune response which typically occurs 4-10 days after exposure to heparin; it can lead to serious complications and be life-threatening. This condition occurs in up to 5% of those who are exposed to heparin. Characteristic signs of HIT are a drop in platelet count of greater than 50% and/or the formation of new blood clots during heparin therapy. The first step of treatment is to discontinue and avoid all heparin products immediately. Often, affected individuals require another medicine to prevent blood clotting ( anticoagulants ).

MalaCards based summary : Heparin-Induced Thrombocytopenia, also known as hit, is related to pulmonary embolism and purpura. An important gene associated with Heparin-Induced Thrombocytopenia is PF4 (Platelet Factor 4), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Collagen chain trimerization. The drugs Certoparin and Desirudin have been mentioned in the context of this disorder. Affiliated tissues include heart, kidney and liver, and related phenotypes are hypercoagulability and autoimmune thrombocytopenia

Wikipedia : 73 Heparin-induced thrombocytopenia (HIT) is the development of thrombocytopenia (a low platelet count),... more...

Sources

Related Diseases for Heparin-Induced Thrombocytopenia

About this section

Diseases related to Heparin-Induced Thrombocytopenia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 341)
# Related Disease Score Top Affiliating Genes
1 pulmonary embolism 31.1 SERPINC1 F3 F10
2 purpura 30.9 SERPINC1 F3
3 disseminated intravascular coagulation 30.8 SERPINC1 F3 F10
4 thrombocytopenia 30.7 SERPINC1 PF4 FCGR2A F3 F10 CD40LG
5 thrombocytopenia due to platelet alloimmunization 30.6 PF4 FCGR2A
6 thrombophilia due to thrombin defect 30.6 SERPINC1 PF4 F3 F10
7 budd-chiari syndrome 30.5 SERPINC1 F3
8 compartment syndrome 30.5 SERPINC1 F3
9 thrombophlebitis 30.5 SERPINC1 F3
10 thrombotic thrombocytopenic purpura 30.5 SERPINC1 F3
11 coronary thrombosis 30.5 SERPINC1 F3
12 intermediate coronary syndrome 30.5 SERPINC1 PF4 F3
13 catastrophic antiphospholipid syndrome 30.3 F3 CD40LG
14 sagittal sinus thrombosis 30.3 SERPINC1 F3
15 infective endocarditis 30.3 PF4 FCGR2A
16 thrombosis 30.3 SERPINC1 PF4 F3 F10 CD40LG
17 endocarditis 30.3 SERPINC1 PF4 FCGR2A
18 acute myocardial infarction 30.3 SERPINC1 PF4 F3
19 thrombocytosis 30.3 SERPINC1 PF4 F3
20 qualitative platelet defect 30.1 PF4 F3
21 thrombophilia 30.1 SERPINC1 PF4 F3 F10
22 platelet aggregation, spontaneous 30.0 SERPINC1 PF4
23 peripheral vascular disease 30.0 SERPINC1 PF4 F3
24 intracranial embolism 30.0 SERPINC1 F3
25 branch retinal artery occlusion 30.0 SERPINC1 F3
26 splenic infarction 29.9 SERPINC1 F3
27 vitamin k deficiency bleeding 29.9 SERPINC1 F3
28 intracranial thrombosis 29.9 SERPINC1 F3 F10
29 papilledema 29.9 SERPINC1 F3
30 nonbacterial thrombotic endocarditis 29.9 SERPINC1 PF4 F3
31 mitral valve stenosis 29.9 SERPINC1 PF4 F3
32 thrombophilia due to activated protein c resistance 29.8 SERPINC1 F3 F10
33 essential thrombocythemia 29.8 SERPINC1 PF4 F3 CD40LG
34 toxic shock syndrome 29.8 SERPINC1 F3 CD40LG
35 antiphospholipid syndrome 29.7 SERPINC1 PF4 F3 F10 CD40LG
36 protein s deficiency 29.6 SERPINC1 F3 F10
37 vascular disease 29.6 SERPINC1 PF4 F3 CD40LG
38 hemorrhagic disease 29.2 SERPINC1 PF4 F3 F10
39 stroke, ischemic 29.2 SERPINC1 PF4 F3 F10
40 myocardial infarction 28.9 SERPINC1 PF4 F3 F10 CD40LG
41 diabetes mellitus 28.7 SERPINC1 PF4 F3 CD40LG
42 lipoprotein quantitative trait locus 28.6 PF4 FCGR2A F3 F10 CD40LG
43 heart disease 28.6 SERPINC1 PF4 F3 CD40LG
44 blood platelet disease 28.2 SERPINC1 PF4 FCGR2A F3 F10 CD40LG
45 limb ischemia 10.6
46 ischemia 10.6
47 acute kidney failure 10.6
48 kidney disease 10.5
49 respiratory failure 10.5
50 aortic aneurysm 10.5

Graphical network of the top 20 diseases related to Heparin-Induced Thrombocytopenia:



Diseases related to Heparin-Induced Thrombocytopenia
Sources

Symptoms & Phenotypes for Heparin-Induced Thrombocytopenia

About this section

Human phenotypes related to Heparin-Induced Thrombocytopenia:

58 31 (show all 15)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hypercoagulability 58 31 hallmark (90%) Very frequent (99-80%) HP:0100724
2 autoimmune thrombocytopenia 58 31 hallmark (90%) Very frequent (99-80%) HP:0001973
3 thromboembolism 58 31 hallmark (90%) Very frequent (99-80%) HP:0001907
4 arterial thrombosis 58 31 frequent (33%) Frequent (79-30%) HP:0004420
5 deep venous thrombosis 58 31 frequent (33%) Frequent (79-30%) HP:0002625
6 increased serum serotonin 58 31 frequent (33%) Frequent (79-30%) HP:0003144
7 myocardial infarction 58 31 occasional (7.5%) Occasional (29-5%) HP:0001658
8 stroke 58 31 occasional (7.5%) Occasional (29-5%) HP:0001297
9 cerebral ischemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002637
10 pulmonary embolism 58 31 occasional (7.5%) Occasional (29-5%) HP:0002204
11 increased inflammatory response 58 31 occasional (7.5%) Occasional (29-5%) HP:0012649
12 disseminated intravascular coagulation 58 31 occasional (7.5%) Occasional (29-5%) HP:0005521
13 mesenteric venous thrombosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0030248
14 abnormal onset of bleeding 58 31 very rare (1%) Very rare (<4-1%) HP:0040231
15 venous thrombosis 58 Frequent (79-30%)

MGI Mouse Phenotypes related to Heparin-Induced Thrombocytopenia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.1 CD40LG F10 F3 FCGR2A PF4 SERPINC1
Sources

Drugs & Therapeutics for Heparin-Induced Thrombocytopenia

About this section

Drugs for Heparin-Induced Thrombocytopenia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 24)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Certoparin Approved, Investigational Phase 4
2
Desirudin Approved Phase 4 120993-53-5
3 Liver Extracts Phase 4
4
Bilirubin Phase 4 635-65-4 5280352
5
Warfarin Approved Phase 3 81-81-2 6691 54678486
6 Danaparoid Approved, Withdrawn Phase 3 308068-55-5, 83513-48-8
7
Rivaroxaban Approved Phase 3 366789-02-8
8
Apixaban Approved Phase 2 503612-47-3 10182969
9 Immunoglobulins Phase 1
10 Antibodies Phase 1
11 Immunologic Factors Phase 1
12
Enoxaparin Approved 9005-49-6 772
13
Tinzaparin Approved 9041-08-1, 9005-49-6 25244225
14
Dalteparin Approved 9005-49-6
15 Heparinoids
16 Fibrin Fibrinogen Degradation Products
17 Fibrin fragment D
18 Immunoglobulins, Intravenous
19 Antibodies, Monoclonal
20 Hemostatics
21 Ecarin
22 Platelet Factor 4
23 Heparin, Low-Molecular-Weight
24
Serotonin Investigational, Nutraceutical 50-67-9 5202

Interventional clinical trials:

(show all 36)
# Name Status NCT ID Phase Drugs
1 Randomized-Double Blind Trial to Assess the Incidence and Clinical Relevance of Heparin-Induced Thrombocytopenia (HIT) Antibodies in Trauma Patients Treated With Unfractionated or Low-Molecular Weight Heparin, the HIT-TRAP Trial Unknown status NCT00196417 Phase 4 Standard heparin (UFH) versus certoparin (LMWH)
2 Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin Completed NCT00039858 Phase 4 Argatroban
3 Argatroban Versus Lepirudin in Critically Ill Patients - A Randomized Double-blind Trial Terminated NCT00798525 Phase 4 Argatroban;Lepirudin
4 A Comparative Clinical and Pharmacoeconomic Study Comparing Argatroban® IV vs Desirudin SC for Patients With Suspected Heparin-Induced Thrombocytopenia (HIT)With or Without Thrombosis Syndrome (HIT/TS) Terminated NCT00787332 Phase 4 Desirudin or Argatroban®
5 Bivalirudin PCI Registry in HIT/HITTS Patients Withdrawn NCT00759083 Phase 4 bivalirudin
6 Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia Withdrawn NCT00603824 Phase 4 fondaparinux;argatroban or lepirudin
7 Multi-Center Single Arm Trial to Determine The Effectiveness of Warfarin Therapy Duration For Heparin-Induced Thrombocytopenia (HIT) Unknown status NCT03147638 Phase 3 Warfarin, NOAC
8 Open-Label Trial to Evaluate the Efficacy and Safety of the Use of Argatroban in Patients With Heparin-Induced Thrombocytopenia Completed NCT00198588 Phase 3 argatroban
9 Anticoagulant Therapy With Bivalirudin in the Performance of PCI in Patients With Heparin-Induced Thrombocytopenia Completed NCT00043940 Phase 3 bivalirudin
10 An Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study to Evaluate the Safety and Efficacy of Danaparoid vs Argatroban in Treatment of Subjects With Acute HIT (HITSOVA Study) Active, not recruiting NCT03809481 Phase 3 Danaparoid Sodium;Argatroban
11 Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia Terminated NCT01598168 Phase 3 Rivaroxaban
12 An Open-label, Multi-centre, Clinical Study to Collect Information on the Clinical Use of Argatroban in Patients With Heparin Induced Thrombocytopenia (HIT) Type II Who Require Parenteral Antithrombotic Therapy Completed NCT00861692 Phase 2 argatroban
13 A Phase II Trial Using Fondaparinux in Patients With Confirmed or Suspected Heparin-Induced Thrombocytopenia (HIT) Terminated NCT00673439 Phase 2 fondaparinux;warfarin
14 A Phase II Study to Evaluate the Efficacy and Safety of Apixaban in the Treatment of Heparin Induced Thrombocytopenia (HIT) Terminated NCT03594045 Phase 2 Apixaban
15 A Pilot Dose-finding and Pharmacokinetic Study of Fondaparinux in Children With Deep Vein Thrombosis or Heparin-induced Thrombocytopenia Completed NCT00412464 Phase 1 Fondaparinux
16 Improving the Diagnosis of Heparin-Induced Thrombocytopenia: Utility of the 4T's Score and Evaluation of New Rapid Assays Completed NCT00489437 Phase 1
17 Inzidenz Und Art Heparin-induzierter Hautveränderungen Unknown status NCT00510432
18 A Multicenter, Prospective Cohort Study to Determine the Prevalence and Profile of Heparin-Induced Thrombocytopenia in Patients Undergoing Cardiovascular Surgery or Percutaneous Coronary Intervention Unknown status NCT00198575
19 Generation of HIT-antibodies Without Prior Heparin Exposure Following Orthopedic Surgery (Subgroup Study) (Change of Coagulation Parameters Under Exposition With New Anticoagulants [Title of the Main Study]) Unknown status NCT01102790
20 Prospectively Validating the 4Ts and Chong Score for Heparin Induced Thrombocytopenia Unknown status NCT00946400
21 Thrombotic Biomarkers to Predict Thrombosis in Heparin-induced Thrombocytopenia Unknown status NCT03269019
22 Implementation of Clinical Pharmacist-led Inpatient Anticoagulation Stewardship Program in An Egyptian Tertiary Care Hospital Unknown status NCT03812848
23 Heparin-induced Thrombocytopenia (HIT II) in Liver Transplant Recipients: a Prospective Multivariate Analysis of Prognostic Factors and Haemostaseological Findings Completed NCT01654848
24 Evaluation of Automated Immunoassay, Particle Gel Immunoassay and Pretest Scoring Systems (4Ts and HEP Scores) in the Diagnosis of Heparin-induced Thrombocytopenia in Surgical Critically Ill Patients Completed NCT02790567
25 Study to Compare the Heparin Induced Thrombocytopenia Rates Associated With Heparin and Low Molecular Weight Heparin Usage as Well as Evaluate the Economic and Long-Term Clinical Burden of Heparin Induced Thrombocytopenia. Completed NCT00456001
26 Heparin-Induced Thrombocytopenia : Development and Validation of a Predictive Clinical Score: a Prospective Multicenter Study Under the Auspices of the French Haemostasis and Thrombosis Study Group (GEHT)in Cooperation With the French Association of Regional PharmacoVigilance Center (AFCRPV) Completed NCT00748839
27 Immunogenetics of Heparin-Induced Thrombocytopenia: Aim 2 Completed NCT02526485
28 Heparin-Induced Thrombocytopenia - Retrospective Analysis of Data on Incidence and Outcomes Study (HIT-RADIO Study) Completed NCT01178333
29 Systematische Dokumentation Von Patienten Mit Akutem HIT-Verdacht Completed NCT01304238 lepirudin;danaparoid;argatroban;fondaparinux
30 A 3 Year Retrospective Heparin Induced Thrombocytopenia Registry (HIT) at Brigham and Women's Hospital. Completed NCT00456326
31 Prognosis Related to Induced Thrombopenia With Heparin Under Venoarterial ECMO in Reanimation Completed NCT03979625
32 Heparin Antibodies in Intensive Care Unit Patients (HAICU) Completed NCT00283322
33 Pharmacogenomics of Heparin-Induced Thrombocytopenia Recruiting NCT02717039
34 Argatroban Monitoring in Critically Ill Patients: Evaluation of a Novel Ecarin-based Bedside Test Recruiting NCT04751357
35 Optimizing the Diagnosis of Heparin Induced Thrombocytopenia Using Quantified Anti-Platelet Factor 4 Immunological Testing: A Pilot Multicentre Cohort Study Recruiting NCT03148912
36 Evaluation of the Intra-observer Agreement of the HEP Score in Surgical Intensive Care. Not yet recruiting NCT04782843

Search NIH Clinical Center for Heparin-Induced Thrombocytopenia

Sources

Genetic Tests for Heparin-Induced Thrombocytopenia

About this section
Sources

Anatomical Context for Heparin-Induced Thrombocytopenia

About this section

MalaCards organs/tissues related to Heparin-Induced Thrombocytopenia:

40
Heart, Kidney, Liver, Pituitary, Endothelial, Lung, Colon
Sources

Publications for Heparin-Induced Thrombocytopenia

About this section

Articles related to Heparin-Induced Thrombocytopenia:

(show top 50) (show all 3875)
# Title Authors PMID Year
1
A case of light chain (AL) amyloidosis with heart failure, renal dysfunction, and heparin-induced thrombocytopenia successfully treated with peritoneal dialysis. 61
33113095 2021
2
Early Identification of Argatroban Resistance and the Consideration of Factor VIII. 61
31694454 2021
3
Thrombin Inhibition by Argatroban: Potential Therapeutic Benefits in COVID-19. 61
32870433 2021
4
A comparative study of platelet factor 4-enhanced platelet activation assays for the diagnosis of heparin-induced thrombocytopenia. 61
33387395 2021
5
Argatroban Anticoagulation for Adult Extracorporeal Membrane Oxygenation: A Systematic Review. 61
33653194 2021
6
Percutaneous Right Ventricular Assist Device Using the TandemHeart ProtekDuo: Real-World Experience. 61
33771937 2021
7
[Spontaneous adrenal hematomas. Retrospective analysis of 20 cases from a tertiary center]. 61
33775473 2021
8
Using information theory to optimize a diagnostic threshold to match physician-ordering practice. 61
33766781 2021
9
Heparin-induced thrombocytopenia and COVID-19. 61
33747413 2021
10
Serotonin-release assay-positive but platelet factor 4-dependent enzyme-immunoassay negative: HIT or not HIT? 61
33326124 2021
11
Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial. 61
33691765 2021
12
Conformation-Crooking CXCL4 to Unravel Autoimmune Heparin-Induced Thrombocytopenia. 61
33385179 2021
13
Heparin-induced thrombocytopenia leading to a diagnosis of essential thrombocythemia. 61
33709631 2021
14
An Optimized and Standardized Rapid Flow Cytometry Functional Method for Heparin-Induced Thrombocytopenia. 61
33805718 2021
15
Functional Flow Cytometric Assay for Reliable and Convenient Heparin-Induced Thrombocytopenia Diagnosis in Daily Practice. 61
33806140 2021
16
Superior outcomes with Argatroban for heparin-induced thrombocytopenia: a Bayesian network meta-analysis. 61
33774764 2021
17
Characterization of New Monoclonal PF4-Specific Antibodies as Useful Tools for Studies on Typical and Autoimmune Heparin-Induced Thrombocytopenia. 61
33086397 2021
18
Fondaparinux-associated Thrombocytopenia. 61
33679958 2021
19
Heparin-induced thrombocytopenia during IgA vasculitis: a case report. 61
33732481 2021
20
Heparin-induced thrombocytopenia: pathophysiology, diagnosis and treatment. 61
33736552 2021
21
A prospective, blinded study of a PF4-dependent assay for HIT diagnosis. 61
32898858 2021
22
Low-Dose Intravenous Heparin Infusion After Aneurysmal Subarachnoid Hemorrhage is Associated With Decreased Risk of Delayed Neurological Deficit and Cerebral Infarction. 61
33269390 2021
23
Propofol Safety in Anticoagulated and Nonanticoagulated Patients During Extracorporeal Membrane Oxygenation. 61
32639256 2021
24
Quantitative and Qualitative Platelet Derangements in Cardiac Surgery and Extracorporeal Life Support. 61
33561947 2021
25
Side effects of continuous intra-arterial infusion of nimodipine for management of resistant cerebral vasospasm in subarachnoid hemorrhage patients: A systematic review. 61
33652066 2021
26
Acute limb ischemia in a patient with pre-fibrotic myelofibrosis complicated by heparin-induced thrombocytopenia and thrombosis - case report and systematic review of dabigatran use. 61
32597318 2021
27
Platelet FcγRIIA in immunity and thrombosis: Adaptive immunothrombosis. 61
33587783 2021
28
Venous Thromboembolism Chemoprophylaxis in Burn Patients: A Literature Review and Single-Institution Experience. 61
32842151 2021
29
A 47-Year Old Woman With Rapidly Progressive Hypoxemic Respiratory Failure. 61
33563457 2021
30
COVID-19 patients often show high-titer non-platelet-activating anti-PF4/heparin IgG antibodies. 61
33550713 2021
31
Platelet-activating immune complexes identified in critically ill COVID-19 patients suspected of heparin-induced thrombocytopenia. 61
33639037 2021
32
Is COVID-19 an Independent Risk Factor for Heparin-Induced Thrombocytopenia? 61
33758713 2021
33
Heparin for preventing adverse obstetrical outcomes in pregnant women with antiphospholipid syndrome, a systematic review and meta-analysis. 61
33171281 2021
34
A case report of successful transition from argatroban to warfarin using DOAC-stop in heparin induced thrombocytopenia (HIT). 61
33610318 2021
35
Treatment and outcomes of heparin-induced thrombocytopenia (HIT) in patients with neoplasm, a case series. 61
33582956 2021
36
Intravenous Immune Globulin (IVIG) for Treatment of Autoimmune Heparin-Induced Thrombocytopenia: A Systematic Review. 61
32693627 2021
37
Heparin-Induced Thrombocytopenia: A Review of New Concepts in Pathogenesis, Diagnosis, and Management. 61
33578859 2021
38
GTH 2021 State of the Art-Cardiac Surgery: The Perioperative Management of Heparin-Induced Thrombocytopenia in Cardiac Surgery. 61
33588456 2021
39
Clinical outcomes of cardiac surgery patients undergoing therapeutic plasma exchange for heparin-induced thrombocytopenia. 61
32965049 2021
40
A population-based analysis on the use of therapeutic plasma exchange and intravenous immunoglobulin in heparin-induced thrombocytopenia. 61
33621860 2021
41
Medical Management of Heparin-Induced Thrombocytopenia Causing Acute Adrenal Insufficiency. 61
33754099 2021
42
A multicentre assessment of contemporary laboratory assays for heparin induced thrombocytopenia. 61
33032809 2021
43
Correction to the article "Viscoelastic Tests in the Evaluation of Haemostatic Disorders in SARS-CoV-2 Infection", Published on Acta Med Port 2021 Jan;34(1):35-46. 61
33618796 2021
44
Off-target binding of an anti-amyloid beta monoclonal antibody to platelet factor 4 causes acute and chronic toxicity in cynomolgus monkeys. 61
33596779 2021
45
[Towards new indications for direct oral anticoagulants]. 61
33443825 2021
46
Heparin induced thrombocytopenia: position paper from the Italian Society on Thrombosis and Haemostasis (SISET). 61
33370230 2021
47
Heparin-Induced Thrombocytopenia: A Focus on Thrombosis. 61
33267665 2021
48
Coronary thrombosis due to heparin-induced thrombocytopenia after percutaneous coronary intervention: Easy to miss, uneasy to prevent. 61
33489138 2021
49
Acute Severe Thrombocytopenia Event Associated with Trimethoprim/Sulfamethoxazole Use. 61
33732872 2021
50
Pragmatic Recommendations for the Management of Anticoagulation and Venous Thrombotic Disease for Hospitalized Patients with COVID-19 in Low- and Middle-Income Countries. 61
33432908 2021
Sources

Variations for Heparin-Induced Thrombocytopenia

About this section
Sources

Expression for Heparin-Induced Thrombocytopenia

About this section
Search GEO for disease gene expression data for Heparin-Induced Thrombocytopenia.
Sources

Pathways for Heparin-Induced Thrombocytopenia

About this section

Pathways related to Heparin-Induced Thrombocytopenia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Response to elevated platelet cytosolic Ca2+ 65
Show member pathways
 12.53 SERPINC1 PF4 F3 F10
2
Collagen chain trimerization 65
Show member pathways
 12.23 SERPINC1 F3 F10
3
Complement and coagulation cascades 36 1
11.29 SERPINC1 F3 F10
4
Formation of Fibrin Clot (Clotting Cascade) 65
Show member pathways
 11.13 SERPINC1 PF4 F3 F10
5
IgA-Producing B Cells in the Intestine 64
11.08 FCGR2A CD40LG
Sources

GO Terms for Heparin-Induced Thrombocytopenia

About this section

Cellular components related to Heparin-Induced Thrombocytopenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.55 SERPINC1 PF4 F3 F10 CD40LG
2 collagen-containing extracellular matrix GO:0062023 9.43 SERPINC1 PF4 F3
3 extracellular space GO:0005615 9.35 SERPINC1 PF4 F3 F10 CD40LG
4 intrinsic component of external side of plasma membrane GO:0031233 8.62 F3 F10

Biological processes related to Heparin-Induced Thrombocytopenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 blood coagulation GO:0007596 9.33 SERPINC1 F3 F10
2 blood coagulation, extrinsic pathway GO:0007598 8.96 F3 F10
3 hemostasis GO:0007599 8.8 SERPINC1 F3 F10

Molecular functions related to Heparin-Induced Thrombocytopenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 8.62 SERPINC1 F3
Sources

Sources for Heparin-Induced Thrombocytopenia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....